Cardiac Science Announces Financing.

IRVINE, Calif.--(BW HealthWire)--Nov. 2, 1998--Cardiac Science Inc. (OTC: DFIB), the developer of the Powerheart(R) fully automatic external defibrillator-monitor and Cardiac Arrest Detection and Defibrillation Software(TM), Monday announced it has completed a private placement of 500,000 shares of common stock and warrants to purchase 125,000 shares of common stock at $2.50 per share, for an aggregate purchase price of $1 million.

The investor has agreed to make an additional investment of $1.5 million, under similar terms, upon the completion of a strategic partnering agreement.

"The proceeds from this financing will enable us to complete the commercial version of the Powerheart(R), begin production and commence marketing activities in advance of worldwide introduction scheduled for early 1999," said Raymond W. Cohen, president and chief executive officer.

Cardiac Science's products are the only external devices cleared by the FDA that continuously monitor in-hospital patients at risk of sudden cardiac arrest, instantly detect life threatening heart rhythms and when appropriate, deliver defibrillation shocks within seconds without human intervention to jump-start the heart.

Response-time to first defibrillation is critical. Numerous studies document inherent delays in hospital resuscitation resulting in 15 percent survival rates of patients who suffer in-hospital cardiac arrest. The American Heart Association, as well as the world's major resuscitation councils, determined that rapid defibrillation is the single most important therapy for the treatment of cardiac arrest. For each minute that passes after the onset of a life-threatening arrhythmia, the chance of survival declines 10-15 percent.

In controlled multicenter clinical studies, the Powerheart(R) demonstrated a response time of 21 seconds from onset to first defibrillation. Early rhythm assessment and immediate defibrillation means significantly increased survival rates, reduced damage to heart and other vital organs, including the brain, which may lessen debilitation and quicken recovery periods.

For more information, visit the company's Internet sites at www.cardiacscience.com and www.diagnosticmonitoring.com.

This news release contains forward-looking statements, including but not limited to those regarding Cardiac Science's ability to improve patient-care, increase survival rates for in-hospital cardiac arrest victims, and reduce patient care costs. Actual results could vary materially from the description contained herein due to many factors, including hospital operations, market and clinical users acceptance of new and existing products, impact of competitive products and pricing, changing market conditions, and risks detailed in the company's Form 10-KSB for the year ending Dec. 31, 1997 and other documents filed with the Securities and Exchange Commission. The cheart(R), AECD(R), AECD Tachyarrhythmia Detection Software(TM) and Cardiac Arrest Detection and Defibrillation Software(TM), are trademarks of Cardiac Science Inc.